Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Optimization, Formulation, and Stability of Topical Rapamycin Used for Rare Tuberous Sclerosis Disease: from Ointment to Liposomes ; volume:18 ; number:4 ; day:5 ; month:12 ; year:2023 ; pages:2287-2293 ; date:12.2023
Journal of pharmaceutical innovation ; 18, Heft 4 (5.12.2023), 2287-2293, 12.2023
- Creator
-
Cortell-Fuster, Clara
Martínez-Gómez, María Amparo
Cercós-Lleti, Ana Cristina
Climente-Martí, Mónica
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12247-023-09792-9
- URN
-
urn:nbn:de:101:1-2024032121080147084581
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cortell-Fuster, Clara
- Martínez-Gómez, María Amparo
- Cercós-Lleti, Ana Cristina
- Climente-Martí, Mónica
- SpringerLink (Online service)
Other Objects (12)
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Multifunctional liposomes: Microscale formulation, modification and in vitro interaction
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Formulation of cost-effective medium and optimization studies for enhanced production of rapamycin
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Multifunctional liposomes: Microscale formulation, modification and in vitro interaction
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Formulation of cost-effective medium and optimization studies for enhanced production of rapamycin
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations
Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
Multifunctional liposomes: Microscale formulation, modification and in vitro interaction
Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models
Besifloxacin liposomes with positively charged additives for an improved topical ocular delivery
Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
Formulation of cost-effective medium and optimization studies for enhanced production of rapamycin
Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis